Vimarsana
Biggest News Aggregation in the World

Page 6 - Myeloma Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Myeloma Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Myeloma Program Today - Breaking & Trending Today

Health News | Experimental Cancer Therapy Shows 73 Pc Success Rate in Trials: Study - Vimarsana News

Health News | Experimental Cancer Therapy Shows 73 Pc Success Rate in Trials: Study

Get latest articles and stories on Health at LatestLY. The treatment, which is referred to as a "bispecific antibody," binds to both T cells and multiple myeloma cells and instructs the T cells, which are white blood cells that can be used to fight off diseases Health News | Experimental Cancer Therapy Shows 73 Pc Success Rate in Trials: Study.

World-Renowned Myeloma Expert, Dr. Ivan Borrello, Joins TGH Cancer Institute to Lead Its Bone Marrow Transplant (BMT)and Cell Therapies Program - Vimarsana News

World-Renowned Myeloma Expert, Dr. Ivan Borrello, Joins TGH Cancer Institute to Lead Its Bone Marrow Transplant (BMT)and Cell Therapies Program

/PRNewswire/ -- Tampa General Hospital is announcing its appointment of Dr. Ivan Borrello to the TGH Cancer Institute. Borrello is a world-class translational...

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Vimarsana News

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Press Release - Vimarsana News

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Press Release

Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen Pharm

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Vimarsana News

Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...